Addiction Medicine: Beyond the Abstract

In today's Episode Rewind, we're revisiting our talk with Dr. Pouya Azar talking about his article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review.

Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar’s clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes.

-

Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative

In today's episode, Dr. Mark McGovern and Dr. Berkeley Franz stop by the show to discuss their latest article Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs, featured in the July/August issue of the Journal of Addiction Medicine.

 

Article Link: Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs

In this episode, infectious diseases physician Dr. Liz Novick stops by to discuss her recent study Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-related Wounds featured in the May/June issue of the Journal of Addiction Medicine.

 

Article Link: Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-related Wounds

In today's episode, Drs. Nicole Malette and Paxton Bach join the show to discuss their new article Approaches for Managing Benzodiazepine Dependence Arising From Use of the Adulterated Opioid Supply: A Delphi Technique featured in the July/August issue of the Journal of Addiction Medicine.

 

Article Link: Approaches for Managing Benzodiazepine Dependence Arising From Use of the Adulterated Opioid Supply: A Delphi Technique

In this episode, Dr. Jeanmarie Perrone sits down to discuss her new article The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine featured in the May/June issue of the Journal of Addiction Medicine.

Jeanmarie Perrone, MD is a Professor in the Department of Emergency Medicine, the Director of Addiction Toxicology, and the founding Director of the Penn Center for Addiction Medicine and Policy, all at the University of Pennsylvania. Dr. Perrone has led multiple initiatives through the emergency department for the initiation of treatment for substance use disorders.  Dr. Perrone has been recognized with several awards for education and mentorship and is board certified in emergency medicine, medical toxicology and addiction medicine. 

Article Link: The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine